Antares Pharma Inc (ATRS.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Antares Pharma Q3 loss per share $0.03
- BRIEF-Antares Pharma receives complete response letter from FDA for Xyosted
- BRIEF-Antares Pharma says received FDA letter regarding deficiencies of its drug Xyosted
- BRIEF-Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals
- BRIEF-Antares Pharma entered sales agreement with cowen and co to offer, sell shares of its common stock, par value $0.01/share- SEC Filing